A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

Condition studied

Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

Investigational medicinal product(s)

Eligibility

Primary endpoint

Confirmed Objective Response (OR) as Assessed by Independent Central Review (ICR)

Endpoint detail

Duration of Response (DoR) as Assessed by ICR in participants with MET amplified positivity determined by F1CDx testing, Progression-Free Survival (PFS) as Assessed by ICR in participants with MET amplified positivity determined by F1CDx testing, Disease Control (DC) as Assessed by ICR based on RECIST v1.1 or RANO criteria as appropriate to tumor type in subjects with MET amplified positivity determined by F1CDx testing, OS in Participants with MET Amplified Positivity Determined by F1CDx Testing